Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 
 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
03/16 BIOGEN : Appoints Anirvan Ghosh Senior Vice President, Research and Early Develo..
03/01 BIOGEN : Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel..
02/28 BIOGEN : to Present at the Cowen & Company 37th Annual Health Care Conference
02/15 BIOGEN : to Present at the 2017 RBC Capital Markets Global Healthcare Conference
02/07 BIOGEN : to Present at the Leerink Partners 6th Annual Global Healthcare Confere..
02/02 BIOGEN INC : Spin off
02/01 BIOGEN : Completes Separation of Global Hemophilia Business, Bioverativ
01/26DJBIOGEN : Profit Skids, Revenue Grows Less Than Expected
01/26 BIOGEN : Reports 2016 Revenues of $11.4 Billion
01/23BIOGEN INC : annual earnings release
More news
Sector news : Biopharmaceuticals
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Biopharmaceuticals
News from SeekingAlpha
03/26 With Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector
03/22 Court Victory Benefits Biogen And Its Tecfidera Rival Alike
03/21 Biogen victory makes company more attractive M&A target - RBC
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Biogen up 1% on favorable patent decision
Advertisement
Financials ($)
Sales 2017 11 281 M
EBIT 2017 6 076 M
Net income 2017 4 024 M
Finance 2017 41,4 M
Yield 2017 -
P/E ratio 2017 14,70
P/E ratio 2018 13,28
EV / Sales 2017 5,26x
EV / Sales 2018 4,79x
Capitalization 59 348 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 317 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC5.16%59 348
CSL LIMITED23.00%42 869
ALEXION PHARMACEUTICAL..-2.53%26 787
BIOMARIN PHARMACEUTICA..5.47%15 103
GRIFOLS SA14.67%14 943
CHONGQING ZHIFEI BIOLO..--.--%4 160
More Results